Congenital Myasthenia
Gene: ALG2
ClinGen: 'STRONG' for ALG2-congenital disorder of glycosylation
Patients have a range of range of symptoms, such as developmental delay, seizures, poor vision, coagulopathy, and delayed myelinization. Patients may also present with congenital myasthenic syndromes (CMS) which characterized by fatigable muscle weakness.Created: 2 Oct 2025, 12:30 p.m. | Last Modified: 2 Oct 2025, 12:30 p.m.
Panel Version: 1.13
      Mode of inheritance
      BIALLELIC, autosomal or pseudoautosomal
    
      Phenotypes
      Congenital disorder of glycosylation, type Ii, MIM# 607906
    
Publications
Two families reported, same, likely founder variant. Note there is another individual reported with a multi-system CDG disorder, no mention of myasthenia.Created: 23 Oct 2020, 5:07 p.m. | Last Modified: 23 Oct 2020, 5:07 p.m.
Panel Version: 0.22
      Mode of inheritance
      BIALLELIC, autosomal or pseudoautosomal
    
      Phenotypes
      Myasthenic syndrome, congenital, 14, with tubular aggregates, MIM# 616228
    
Publications
Gene: alg2 has been classified as Green List (High Evidence).
Tag founder tag was added to gene: ALG2.
Gene: alg2 has been classified as Amber List (Moderate Evidence).
Phenotypes for gene: ALG2 were changed from Congenital disorder of glycosylation CDG type Ii, 607906; Myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 to Myasthenic syndrome, congenital, 14, with tubular aggregates, 616228
Publications for gene: ALG2 were set to
Gene: alg2 has been classified as Amber List (Moderate Evidence).
gene: ALG2 was added gene: ALG2 was added to Congenital Myaesthenic Syndrome_RMH. Sources: Royal Melbourne Hospital,Expert Review Green Mode of inheritance for gene: ALG2 was set to BIALLELIC, autosomal or pseudoautosomal Phenotypes for gene: ALG2 were set to Congenital disorder of glycosylation CDG type Ii, 607906; Myasthenic syndrome, congenital, 14, with tubular aggregates, 616228